Daniel Thomas

As global baby gear giant Joie enters Canada, it's not just about strollers. It's a test of retail strategy, a challenge to safety standards, and a bold move in a multi-billion dollar market.

T1 Energy will supply Clearway with 641MW of domestically-celled modules, a landmark deal fueled by policy incentives and a strategic pivot from global risks.

The FDA has fast-tracked a novel peanut allergy therapy from Aravax, signaling a major shift in the multi-billion dollar race to find a lasting solution.

A massive conditional loan to PDW signals Washington's urgent push to end its reliance on foreign drone parts and rebuild its defense industrial base.

Abu Dhabi's healthcare giant reports a 20% profit jump, fueled by aggressive European expansion. Its strategy reveals a blueprint for a new kind of global power.

In a landmark independent test, invideo's Agent One outperformed heavily funded rivals, signaling a new era where technical depth, not deep pockets, defines the AI video race.

Brazil's steel giant CSN is offering a rich deal to swap debt, extending its financial runway. But is the high cost a savvy move or a sign of pressure?

GigaromAI's new no-code platform promises to give individuals institutional-grade trading power. But does this democratization of AI signal a new era or a high-tech gamble?

With strong H1 growth, heritage manager Kaleon isn't just polishing its family-owned gems. A new third-party deal and bold financial moves signal a strategic pivot.

As the AI boom's energy and water use soars, cloud provider Nebius details a blueprint for responsible scaling, blending engineering efficiency with community benefits.

eBay's acquisition of Depop isn't just about clothes; it's a high-stakes play for relevance, a bid to capture the circular economy, and a test of survival.

As Dollar General preps its Q2 earnings, all eyes are on what its results will reveal about inflation, consumer shifts, and the health of the U.S. economy.

Cinemark shattered records with its first-ever billion-dollar quarter, proving strategic investments in premium experiences can defy the streaming era.

With FDA clearance for IKS04, Iksuda Therapeutics unveils a novel co-dosing strategy to deliver a potent payload past notorious tumor barriers.

A new AI model is mining millions of patient notes for cancer data once thought inaccessible, promising to accelerate research and transform patient care.

The hire of Chris Cheng, with his background at Uber and Zoom, signals Cardlytics is fortifying its legal defenses to navigate data privacy and fuel its next chapter.

SR Bancorp's headline earnings fell, but a look beyond one-time events reveals a bank firing on all cylinders with robust loan growth and a bold capital strategy.

Nexo has pioneered a partner-led model for MiCAR compliance, splitting custody and brokerage. Is this the new standard for global crypto firms in the EU?

A 49% stock plunge and a major acquisition write-down have thrust GeneDx into legal turmoil. We deconstruct the securities fraud claims and what they reveal.

As Bakkt prepares its Q2 results, the fintech firm faces a critical test: can its pivot to AI and global payments justify its vision for a new financial system?